News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Biotech Bay
Geron Corporation: Recent Advances in Cellular Reprogramming
November 21, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today commented on the impact of recent advances in cellular reprogramming on the development of human embryonic stem cell (hESC)-based therapies.
Twitter
LinkedIn
Facebook
Email
Print
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
·
4 min read
·
Lorenzo Soliman
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
·
3 min read
·
Greg Slabodkin
Business
BridgeBio Spins Out Oncology Company with $200M in Financing
May 2, 2024
·
2 min read
·
Tyler Patchen
Biotech Bay
BMS Taps Cellares in $380M CAR T Cell Therapy Manufacturing Agreement
April 22, 2024
·
2 min read
·
Tyler Patchen
